FDA approved Hemangeol (propranolol) for Proliferating Infantile HemangiomaFDA approved first drug to treat infantile hemangioma in babies

Propranolol is a beta-adrenergic blocker. The exact mechanism by which it induces regression of infantile hemangiomas is not fully established, but it is thought to involve vasoconstriction, inhibition of angiogenesis, and blockade of pro-growth signals.

Hemangeol is indicated for the treatment of proliferating infantile hemangioma requiring systemic therapy. It is intended for infants aged 5 weeks to 5 months at initiation. The label excludes infants with certain severe forms (life-threatening, function-threatening, or ulcerated with pain and lack of response to simple wound care) from the pivotal trial, but a second uncontrolled study included such cases.

- Initiate treatment at ages 5 weeks to 5 months. - Starting dose: 0.15 mL/kg (0.6 mg/kg) twice daily, at least 9 hours apart. - After 1 week: increase to 0.3 mL/kg (1.1 mg/kg) twice daily. - After 2 weeks: increase to maintenance dose of 0.4 mL/kg (1.7 mg/kg) twice daily, continue for 6 months. - Readjust dose periodically as weight increases. - Administer orally during or right after a feeding. Skip the dose if the child is not eating or is vomiting. - Monitor heart rate and blood pressure for 2 hours after initiation or dose increases. - If hemangiomas recur, treatment may be re-initiated. - Supplied with an oral dosing syringe; may be diluted in a small quantity of milk or fruit juice if necessary.

A randomized, double-blind study in 460 infants (aged 35 days to 5 months) compared four Hemangeol regimens (1.2 or 3.4 mg/kg/day in twice daily divided doses for 3 or 6 months) to placebo. The primary efficacy endpoint was complete or nearly complete resolution of the target hemangioma at Week 24, assessed by blinded centralized review of photographs. In the group receiving 3.4 mg/kg/day for 6 months, 60% (61/101) achieved this endpoint versus 4% (2/55) on placebo (p <0.0001). Response rates did not differ by age, sex, or hemangioma site. Among responders, 10% required retreatment for recurrence. A second uncontrolled study in 23 patients with more severe hemangiomas (including function-threatening, large facial, or ulcerated lesions) showed target lesion resolution in 36% by 3 months.

Contraindications include: premature infants with corrected age <5 weeks; infants weighing <2 kg; known hypersensitivity to propranolol or excipients; asthma or history of bronchospasm; heart rate <80 beats per minute, greater than first degree heart block, or decompensated heart failure; blood pressure <50/30 mmHg; and pheochromocytoma. To reduce risk of hypoglycemia, administer during or after feeding and skip doses if the child is not eating or is vomiting. Monitor heart rate and blood pressure for 2 hours after initiation or dose increases. Drug interactions: CYP2D6, CYP1A2, or CYP2C19 inhibitors may increase propranolol levels; inducers (e.g., phenytoin, phenobarbital, rifampin) may decrease levels. Corticosteroids may increase hypoglycemia risk; monitor for signs.

Hemangeol is the first FDA-approved treatment for proliferating infantile hemangioma requiring systemic therapy. It offers a standardized oral option for a condition previously managed with off-label beta-blockers, corticosteroids, or surgery. The pivotal trial demonstrated a substantial benefit over placebo, with a number needed to treat of approximately 2 for complete or nearly complete resolution at 6 months. Clinicians should weigh the need for systemic therapy against the potential for adverse effects, particularly bradycardia, hypotension, and hypoglycemia, and adhere to recommended monitoring and administration precautions.